"Not An IVDMIA"
This article was originally published in The Gray Sheet
Executive Summary
It pays to look with some caution nowadays when a company announces plans to launch its gene-based test as a service out of a clinical laboratory without need for FDA go-ahead. Although this has been a tried and true method for getting new assays on the market since the inception of the Clinical Laboratory Improvement Amendments of 1988, FDA has been sharpening its focus on certain laboratory-developed tests, or home brews, in recent years. It's in the midst of developing the in vitro diagnostic multivariate index assay policy, where a certain segment of more complex lab-developed test services will be required to go through FDA review. And, recently, the agency took the Laboratory Corporation of America to task in a warning letter targeting the OvaSure ovarian cancer home brew ("The Gray Sheet" Oct. 27, 2008, p. 10).
You may also be interested in...
LabCorp Pulls OvaSure, But Charges FDA With Overreaching
Laboratory Corporation of America pulled its early-stage ovarian cancer test service from the market last week in response to FDA scrutiny, but the lab giant called the agency's actions leading up to the withdrawal "unprecedented.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.